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ABOUT THE USE IN NUCLEAR MEDICINE OF PHARMACEUTICALS 
ON THE BASIS OF THE ISOTOPE 
18
F AND ITS ACHIEVEMENTS  
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The importance widely used in the world of Radiopharmaceutical: 2-fluoro [
18
F]-2-deoxy-D-glucose (fluo-
rideglucose, 
18
F) for the diagnosis of various diseases using PET and CT imaging are shown. Provides information 
about the levels of specific activity of aqueous solutions containing the isotope 
18
F, the resulting target irradiation-
matrix of Teflon (C2F4) on different linear accelerators of electrons NIK "Accelerator". Emphasis on the need to 
increase the density of the electron flux on the target and find ways of improvement of the methodology for obtain-
ing Radiopharmaceutical, using isotope 
18
F, produced by the photonuclear method. 
PACS: 28.60.+s; 87.Jw 
 
INTRODUCTION 
At present, Ukraine's medical institutions that use 
radionuclide diagnostics have developed a critical situa-
tion due to the almost complete absence of radiophar-
maceuticals (RFPs) of domestic production based on 
radioactive nuclides (isotopes). Although most of the 
diagnostic tools are pharmaceuticals based on techneti-
um 
99m
Tc, a significant (and in some cases determining) 
role in the diagnosis of various diseases is allocated to 
RFPs, "labeled" ultrashort-living (UKZH) radionu-
clides: 
11
C, 
13
N, 
15
O, 
18
F. 
These positron-active radionuclides are widely used 
around the world as sources of 511 keV annihilation 
gamma radiation for positron emission tomographs 
(PET). The undeniable merit of the PET method, using 
the UKZh-isotopes, is that, by providing the operation 
of electronic equipment with high loads (10
5…106 s-1), 
high spatial resolution and a low level of radiation ex-
posure to the patient (fraction of rad) is achieved, and 
itself the examination procedure lasts a few minutes. 
Unfortunately, at the moment there is no universal 
drug that could detect all tumors, so in PET diagnostics 
there is a very large number of drugs. The use of UKZh-
isotopes isotopes for labeling RFPs administered to a 
patient provides two main advantages over other types 
of radioisotope diagnostics. 
First, the label with these isotopes, including the iso-
tope 
11
C, (unlike the isotopes 
99m
Tc or 
123
I used in 
SPECT) does not change the chemical properties of the 
RFPs, therefore they are functional analogues of natural 
metabolites, and the distribution in the body of appropri-
ately selected RFPs adequately reflects parameters of the 
studied biochemical process and/or the functional state of 
the organism. Secondly, the short half-life of these iso-
topes allows multiple studies of the same patient, which 
is of fundamental importance for receptor studies. 
1. APPLICATION  
OF RADIOPHARMA CEUTICAL (RFP)  
2-FLUORO [
18
F] -2-DEOXY-D-GLUCOSE 
(FLUORODEOXYGLUCOSE, 
18
F) 
It is worthwhile to consider more closely the use of 
the 
18
F isotope as a radioactive "tag" when creating RFP 
for PET diagnostics. Tumors are different in nature and 
have different cellular composition, and, consequently, 
have different properties. Unfortunately at the moment 
there is no universal drug that could detect all tumors, 
therefore in PET diagnostics there is a very large num-
ber of drugs. But among the multitude there is one, the 
most universal, which works on a large spectrum of 
tumor pathologies  it is fluorodeoxyglucose or FDG is 
a molecule of glucose in which one hydroxyl group is 
replaced by of radioactive fluorine  18F (Fig. 1).  
 
 
 
 
Fig. 1. Molecule of glucose and molecule FDG 
How does it work and why does FDG accumulate? 
Shorter: glucose is energy! All cells need energy, and 
the cells of the tumor need energy especially, because 
they quickly divide, and for this, the cells of the tumor 
need a lot of energy. Therefore, tumor cells accumulate 
a much larger amount of glucose, and consequently 
FDG. For this reason, in the PET study, we can see 
where the tumor cells are located. 
It should be noted, that unfortunately this drug is 
able to detect not all tumors. It depends on the charac-
teristics of the tumor. For example, FDG works great 
for most lymphomas, many lung tumors, intestinal tu-
mors, breast, melange and many others, but the diagnos-
tic value of FDG in prostate cancer is extremely low. A 
similar situation with a low diagnostic significance of 
FDG is observed in most neuroendocrine tumors. 
Similarly, the capabilities of the device are limited 
and we can not identify one or more cells. The resolu-
tion of the device is limited and the PET study can visu-
alize tumors ranging from 4…6 mm. 
2. PET RESEARCH 
Consider PET/CT studies with FDG, since studies 
with this drug are about 80 percent of all PET research 
in the world. The first of the presented slides (Fig. 2, 
top) shows a pure positron tomogram, next  a com-
bined PET/CT image. It can be seen that in this case 
there is no pronounced pathology. 
Molecule FDG 
Molecule of glucose 
C6H12O6 
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Fig. 2. PET/CT image of the patient 
On the slide (Fig. 2, on the bottom)  a patient with 
Hodgkin's lymphoma, multiple black dots (or red on the 
next slide) show the affected lymph nodes. It should be 
noted that the color solution depends on the specific 
doctor and does not affect the diagnostic value of the 
study. 
How to determine the pathological accumulation of 
the drug on PET/CT and what is SUV? PET allows not 
only to see the tumor process, but also to carry out cer-
tain measurements. If in X-ray computed tomography 
(CT) and magnetic resonance imaging (MRI) measure-
ments are performed in centimeters (millimeters) to 
determine the size of the pathological site. The intensity 
of accumulation of the drug in the pathological organ  
SUV (STANDARDIZED STAGE OF RADIOPHARM 
PREPARATION ACCUMU-LATION) is determined in 
PET diagnostics. 
It should be noted that there are different SUV pa-
rameters and different units of measurement, so in the 
description protocol there should be a link explaining 
this data. 
Fig. 3 shows, for example, a PET image of the pa-
tient's liver patch in a situation with an increased inten-
sity level of the 
18
F isotope. 
 
Fig. 3. SUV=11 
Thus, this parameter shows how many RFPs accu-
mulated in the volume of the tumor focus. What is it 
for? 
First, there are threshold values for which doctors 
are oriented, for a conditional differentiation of the 
norm and pathology. 
Second  the change in SUV against the background 
of treatment helps doctors to conclude on its effective-
ness. That is, if the treatment of SUV is reduced against 
the background, then the treatment works and vice ver-
sa, by how significantly the SUV changes, a conclusion 
is made about the continuation or change of therapeutic 
tactics. 
3. EXPERIMENT 
In the world, a technique for obtaining the 
18
F iso-
tope is widely used by irradiating protons with energy 
10…20 MeV water enriched with a stable isotope of 
oxygen 
18
O according to the reaction 
18
O(p, np)
18
F, 
which makes it possible to obtain fluorinated com-
pounds, for example, fluorodeoxyglucose, 
18
F. 
The task of this study at the initial stage was to de-
termine the feasibility of the 
18
F isotope production by 
the photonuclear method at various linear accelerators 
of electrons existing in the NIC "Accelerator" (NSC 
KIPT AN NASU). As a criterion, the specific activity of 
aqueous solutions, containing the isotope 
18
F, was de-
termined, which is formed as a result of irradiation of 
target matrices from fluoroplastic (fluoropolimer) (C2F4) 
by a gamma-ray beam from a linear electron accelera-
tor. An experimental verification of this possibility was 
carried out at accelerators: LU-10, «EPOS», LU-40m. 
3.1. ACCELERATOR LU-10 
The study of the 
18
F isotope production on the LU-10 
accelerator was carried out, using the output device 
schematically depicted in Fig. 4. 
The output device includes the Bremsstrahlung con-
verter K, the Ф1 filter (4 duralumin plates 2 mm thick 
each) and additional polyethylene filter Ф2 with a 
thickness of ~ 50 mm. Target M1 includes two capsules 
of duralumin, into which a coiled film of fluoroplastic 
with a mass of 1.020 g is placed in water (distillate)  in 
one capsule in the other  a coarse-grained powder of 
fluoroplastic with a mass of 1.000 g. 
Two pieces of dosimetric film are placed on each 
capsule from the side of the beam. The target M1 con-
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sists samples of In, Au, Cd, Hf and Sn, used for dosime-
try of bremsstrahlung of the accelerator. 
At the accelerator LU-10, a mode of 12…13 MeV is 
obtained at the maximum of the spectrum. 
An output device is installed according to the exper-
imental design. 
 
Fig. 4. The circuit of the output device 
The targets were irradiated with a scanned beam 
with a mean current of 200 μA for 30 minutes. 
Results of the experiment: 
1. Weight loss of each ampoule was 0.5 g. 
2. The activity (according to the isotope 
18
F) of an 
aqueous solution of 1 cm
3
, extracted from the capsule 
with the film (C2F4) was 1.85 KBq/g. 
3. The activity (according to the isotope 
18
F) of an 
aqueous solution of 1cm
3
, extracted from the capsule 
with powder (C2F4) was 1.66 KBq/g. 
4. Considering the different amount of water in the 
capsule, we can conclude that the isotope 
18
F is more 
efficiently released to the aqueous phase from the pow-
der. 
5. The neutron flux measured by Au-threshold de-
tectors was: fast neutrons  4.49105 ns-1, slow neutrons 
 2.23106 ns-1. 
3.2. ACCELERATOR "EPOS" 
The scheme of the experiment is shown in Fig. 5. 
The accelerator worked in the mode of scanning an 
electron beam: energy  25 MeV, Іav= 450 мкА, the 
time of irradiation is 110 min. 
A Pb converter, 10 mm thick, was used to obtain the 
flux of gamma rays, which was placed just before the 
irradiated capsule. The current density on the converter 
is 0.25 μA/cm2.. 
Сapsules of duralumin, fluoroplast and copper filled 
with water and fluoroplastic in the form of a film with a 
thickness of 20 μm and coarse-grained powder were 
irradiated. 
To cool the capsules, a "rainwater" flow of water 
was technologically used. 
 
Fig. 5. Irradiation geometry 
The results obtained in the irradiation geometry 
shown in Fig. 5 during the exposure time 110 min, at  
E = 25 MeV and Іav = 450 μA: 
- the activity of 
18
F in the aqueous phase is 
4.1104 Bq/g; 
- the activity of 
18
F in the matrix film is 
1.01106 Bq/g; 
- the activity of 
18
F in the plate-matrix is 
1.05106 Bq/g. 
The yield of the isotope 
18
F in water was 4%. 
3.3. ACCELERATOR LU-40m 
The study of the 
18
F isotope run on the LU-40m ac-
celerator [1] is performed in geometry irradiation of the 
capsule-target containing fluorine plastic, depicted in 
Fig. 6. 
 
Fig. 6. The irradiation scheme of the capsule-target  
at the accelerator LU-40m with water cooling  
of the converter and capsule 
Irradiation regime: energy-36 MeV. The average 
current Iav=4.8 μA. The irradiation time is 30 minutes. 
Converter: Ta (4 plates with gaps total thickness 4mm).  
Target: capsule of fluoroplastic (C2F4), filled with fluo-
rine plastic film with a thickness of 20 μm (weight 
1.82 g) and water (mass  1.27 g). 
The total mass of the capsule in the collection: be-
fore irradiation  30.48 g, after irradiation  30.27 g. 
The "mass defect" of the capsule after irradiation is 
explained by the leakage of heated (up to vapor) water 
from the capsule. 
1. After irradiation, an aqueous "concentrate", acti-
vated with the 
18
F isotope, was extracted from the cap-
sule, with a mass of 0.225 g. 
2. The small amount of the extracted "concentrate" 
is explained (presumably) by the "absorption" of water 
by a fluoroplastic film, under the action of irradiation 
(visually it looked "swollen"). Total mass of the capsule 
in the collection: before irradiation  30.48 g, after irra-
diation  30.27 g. 
The "mass defect" of the capsule after irradiation is 
explained by the leakage of heated (up to vapor) water 
from the capsule. 
3. Specific activity of the 
18
F isotope contained in 
the aqueous medium, calculated for the 60 min irradia-
tion with regard to: the irradiation time, the measure-
ment time, the change in activity during the measure-
ment time and the "holding" (or cooling) time was equal 
1.42106 Bq/g. 
e¯ 
 
Сapsule 
«EPOS»   
Accelerator 
 
  Pb 
ЛУ-10
e-
К
Н2О
Ф1
Uсм
Ф2
М1
E
100
220
220
ISSN 1562-6016. ВАНТ. 2017. №6(112) 136 
Summary table of 
18
F production 
Accelerators 
LU-10  
Accelerator 
«EPOS»  
Accelerator 
LU-40m 
Accelerator 
The accumu-
lated specific 
activity of the 
18F isotope  
in the aqueous 
phase 
1.85103 Bq/g 4.1104 Bq/g 1.42106 Bq/g 
Reserve possibilities for increasing the amount of 
isotope 
18
F: 
- increase in the irradiation time (440 minutes,  
- 4T1/2)  factor ~ 2; 
- increase in the mass of irradiated fluoroplastic-
factor ~ 10; 
-increase in the yield of the 
18
F isotope in water-
factor ~ 5; 
- increase in the average current  factor ~ 100. 
The total factor for increasing the amount of iso-
tope
18
F in the aquatic environment can be ~ 10
4
. 
With the activity of the 
18
F isotope in an aqueous 
medium amounting to ~ Curie, we can speak of "open-
ing opportunities" that provide the creation of the phar-
maceutical preparation "Fluodeoxyglucose, 
18
F" 
СONCLUSIONS 
1. As shown by the conducted studies, at the linear 
accelerators of electrons available in the NSC KIPT, the 
production of specific activities of the 
18
F isotope in an 
aqueous medium (~ Curie) sufficient to create RFP 
"Fluorodeoxyglucose, 
18
F" is possible only under the 
condition of optimizing all the factors that determine the 
amount of the 
18
F isotope. 
2. One of the main factors ensuring the value of the 
18
F isotope under the conditions, described above, is the 
current density on the target. 
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ОБ ИСПОЛЬЗОВАНИИ В ЯДЕРНОЙ МЕДИЦИНЕ РФП НА ОСНОВЕ ИЗОТОПА 18F  
И ВОЗМОЖНОСТИ ЕГО НАРАБОТКИ НА ЛИНЕЙНЫХ УСКОРИТЕЛЯХ ЭЛЕКТРОНОВ  
НИК «УСКОРИТЕЛЬ» 
А.И. Азаров, А.Н. Довбня, М.А. Должек, В.А. Кушнир, В.В. Митроченко, С.А. Пережогин,  
Л.И. Селиванов, В.А. Терещенко, В.Ю. Титов, Д.В. Титов, В.А. Шевченко, Б.И. Шраменко 
Показана значимость широко используемого в мире РФП: 2-фтор[18F-2-дезокси-D-глюкозы (фтордезок-
сиглюкозы, 18F) для диагностики различных заболеваний с применением ПЭТ и КТ-томографии. Приведены 
сведения об уровнях удельной активности водных растворов, содержащих изотоп 18F, образующийся в ре-
зультате облучения  мишеней-матриц из фторопласта (C2F4) на различных линейных ускорителях электро-
нов НИК «Ускоритель». Делается ударение на необходимости повышения плотности потока электронов на 
мишени и поиска путей усовершенствования методологии получения РФП-фтордезоксиглюкозы с исполь-
зованием изотопа 18F, нарабатываемого фотоядерным методом. 
ПРО ВИКОРИСТАННЯ В ЯДЕРНІЙ МЕДИЦИНІ РФП НА ОСНОВІ ІЗОТОПУ 18F  
ТА МОЖЛИВОСТІ ЙОГО НАПРАЦЮВАННЯ НА ЛІНІЙНИХ ПРИСКОРЮВАЧАХ ЕЛЕКТРОНІВ 
НДК «ПРИСКОРЮВАЧ» 
А.І. Азаров, А.М. Довбня, М.А. Должек, В.А. Кушнір, В.В. Мітроченко, С.А. Пережогін,  
Л.І. Селіванов, В.А. Терещенко, В.Ю. Титов, Д.В. Титов, В.А. Шевченко, Б.І. Шраменко 
Показана значимість широко використовуваного в світі РФП: 2-фтор[18F]-2-дезоксі-D-глюкози (фторде-
зоксіглюкози, 18F) для діагностики різних захворювань із застосуванням ПЕТ і КТ-томографіі. Приведені 
відомості про рівні питомої активності водних розчинів, що містять ізотоп 18F, що утворюється в результаті 
опромінення мішеней-матриць з фторопласту (C2F4) на різних лінійних прискорювачах електронів НДК 
«Прискорювач». Робиться наголос на необхідності підвищення щільності потоку електронів на мішені і по-
шуку шляхів удосконалення методології отримання РФП-фтордезоксіглюкози з використанням ізотопу 18F, 
напрацьованого фотоядерним методом. 
